Biogen, which holds the overseas rights to Samsung Bioepis' ophthalmic disease treatment biosimilars ‘Byooviz’ and ‘Opuviz,’ has decided to return the North American rights.
According to the biopharmaceutical industry on the 26th, Biogen has decided to terminate its development and commercialization agreements (DCA) with Bioepis in North America, including the United States and Canada. This information was announced in October of last year but was recently confirmed.
In an announcement last October, Biogen stated that it would return the commercialization rights of Byooviz and Opuviz to Samsung Bioepis. The return grace period is 18 months.
However, Biogen will retain the European rights it holds. Biogen has strengths in the European pharmaceutical distribution market compared to the United States.
This decision seems to be due to the poor performance of Byooviz in the U.S. ophthalmic disease treatment market. Byooviz was launched in the United States in 2022, but it has been affected by the poor sales of the original drug, Lucentis. Opuviz has not yet been launched in the United States.